Plasma klotho levels decrease in both anorexia nervosa and obesity

Amitani, Marie; Asakawa, Akihiro; Amitani, Haruka; Kaimoto, Kaori; Sameshima, Nanami; Koyama, Ken; Haruta, Izumi; Tsai, Minglun; Nakahara, Toshihiro; Ushikai, Miharu; Cheng, Kai‐Chun; Hamada, Shin; Inui, Akio

doi:10.1016/j.nut.2013.02.005

Cited by 36 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies suggest a close relationship between Klotho levels and body weight, especially in patients with obesity or anorexia nervosa. 31,32 Some possible hypotheses to explain such contrasting results could be: (i) the local administration in the CNS in our study, rather than systemic intravenous administration, (ii) 6 months of klotho overexpression is not enough time to observe general physical effects; and/or (iii) the vector dose injected is not sufficient to increase Klotho levels in plasma up to concentrations affecting the skeletal muscle.…”

Section: Discussionmentioning

confidence: 73%

Secreted αKlotho isoform protects against age-dependent memory deficits

et al. 2017

View full text Add to dashboard Cite

αKlotho is a gene regulator of aging, increasing life expectancy when overexpressed and accelerating the development of aging phenotypes when inhibited. In mice, expression levels of the secreted isoform Klotho (s-KL) are very high in the brain, suggesting that s-KL activity may have an important role in the nervous system. Here we study the functional relevance at behavioural level of modifying s-KL levels in the aging brain. We used AAVrh10 vectors to deliver and sustained expression of s-KL in 6-and 12-monthold wild-type C57BL/6J males. This study demonstrates for we believe the first time in vivo that 6 months after a single injection of s-KL into the central nervous system, long-lasting and quantifiable enhancement of learning and memory capabilities are found. More importantly, cognitive improvement is also observable in 18-month-old mice treated once, at 12 months of age. These findings demonstrate the therapeutic potential of s-KL as a treatment for cognitive decline associated with aging.

show abstract

Section: Discussionmentioning

confidence: 73%

Secreted αKlotho isoform protects against age-dependent memory deficits

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In this situation BMI does not reflect an increased fat mass as in the normal population [24]. In fact, attenuation of daily activity could be connected with the decrease in sKlotho [25]. It was also observed that levels of IGF-1 and soluble a-Klotho are different with regard to gender.…”

Section: Prace Oryginalnementioning

confidence: 86%

“…Vitamin D was assessed only in some patients (15 AA, 14 WCA, 16 SCA, and 24 CG) by radioimmunologic assay using a 25OH-Vit.D3-Ria-CT kit (DIAsource, Louvain-la-Neuve, Belgium). We used the following ranges of 25 The intra-and interassay coefficients of variation (CVs) were 7.3% and 7.2%, respectively. Seasonality was based on the date of the blood sample collection.…”

Section: Methodsmentioning

confidence: 99%

“…Semba et al presented no influence of BMI on the concentration of sKlotho [22]. In another small study it was noticed that anorexia nervosa as well as obesity could be responsible for lower levels of sKlotho [23]. It is very important to remember that acromegaly is also associated with a decrease in fat mass and an increase in lean body mass.…”

Section: Prace Oryginalnementioning

confidence: 98%

See 1 more Smart Citation

Rozpuszczalne białko α-Klotho — nowy marker aktywności akromegalii?

Jawiarczyk-Przybyłowska

Halupczok-Żyła

Bolanowski

2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Klotho is a transmembrane protein that attenuates insulin/insulin-like growth factor-1 (IGF-1) signalling and appears to be involved in ageing. Recent data suggest that soluble a-Klotho (sKlotho) is also elevated in acromegaly. The aim of this study was to assess serum levels of sKlotho in patients in relation to the activity of the disease and to compare with the control group. Material and methods: We studied 55 patients with acromegaly and 29 healthy controls (CG). Patients were divided into three subgroups according to minimal GH (growth hormone) concentration during the oral glucose tolerance test (OGTT) and the IGF-1 concentration: a surgically cured acromegalic group (SCA), well-controlled acromegalic group (WCA), and active acromegaly group (AA). In all subjects, blood samples were taken to assess the concentration of sKlotho, GH, IGF-1, and biochemical markers. Results: Soluble a-Klotho was highest in the AA group and lowest in the SCA group. The differences in sKlotho levels were statistically significant when the AA group was compared to the SCA, WCA, and CG groups (p = 0.000, p = 0.002, p = 0.001, respectively). There were no significant differences in sKlotho levels among the SCA, WCA, and CG groups. sKlotho positively correlated with GH levels in the WCA and WCA + SCA groups (r = 0.666, p = 0.009; r = 0.366, p = 0.047, respectively) and with the IGF-1 level in the AA group (r = 0.589, p = 0.021). Conclusions: sKlotho is increased in active acromegaly and normalises after successful treatment. It could be a new biomarker of acromegaly activity. (Endokrynol Pol 2016; 67 (4): 390-396)

show abstract

“…Furthermore, low klotho levels were recently noted in a group of 12 AN patients [23]. We therefore aimed to study the association between klotho serum levels, anthropometric measurements, and GH/IGF-1 axis activity in adolescent female inpatients with AN at the time of hospitalization and following weight rehabilitation.…”

Section: Introductionmentioning

confidence: 97%